Few studies have used the intrathecal/intraventricular route to deliver anti-TNF-α drugs to treat brain disease (Heldmann et al., 2005; Riazi et al., 2008; Medeiros et al., 2010; Shi et al., 2011; Camara et al., 2015). This evidence concerns the gene TNF and brain disorder.